Skip to main content

Table 4 Correlation between clinical data and DTCs, CTCs, and slCTCs after therapy

From: Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy

  Total DTC-positive, n % p Value Total CTC-positive, n % p Value Total slCTC-positive, n % p Value
Tumor size 163 33 (20)   131 11 (8)   88 18 (20)  
 ypTis, ypT0 43 12 (28) 0.25 36 3 (8) 0.86 21 3 (14) 0.50
 ypT1a 15 2 (13)   13 0 (0)   12 1 (8)  
 ypT1b, ypT1c 52 6 (12)   40 4 (10)   26 5 (19)  
 ypT2 41 11 (27)   31 2 (6)   23 7 (30)  
 Above ypT2 12 2 (17)   11 2 (18)   6 2 (33)  
Nodal status 163 33 (20)   131 11 (8)   88 18 (20)  
 yN0 103 26 (25) 0.13 83 6 (7) 0.17 56 11 (20) 0.73
 yN1 44 5 (11)   35 2 (6)   22 4 (18)  
 yN2, yN3 46 2 (13)   13 3 (23)   10 3 (30)  
Histology 163 33 (20)   131 11 (8)   89 18 (20)  
 Ductal 122 28 (23) 1.00 94 9 (10) 0.75 66 14 (21) 0.83
 Lobular 21 5 (24)   19 1 (5)   9 2 (22)  
 Other 20 0 (0)   18 1 (6)   14 2 (14)  
Grade 162 32 (20)   130 11 (8)   88 18 (20)  
 I 11 2 (18) 0.95 9 2 (22) 0.35 3 1 (33) 0.85
 II 72 15 (21)   55 4 (7)   39 8 (21)  
 III 79 15 (19)   66 5 (8)   46 9 (20)  
ER status 165 33 (20)   133 11 (8)   90 18 (20)  
 Negative 52 14 (27) 0.13 43 1 (2) 0.12 30 3 (10) 0.11
 Positive 113 19 (17)   90 10 (11)   60 15 (25)  
PR status 165 33 (20)   133 11 (8)   90 18 (20)  
 Negative 62 17 (27) 0.07 49 2 (4) 0.20 35 5 (14) 0.28
 Positive 103 16 (16)   84 9 (11)   55 13 (24)  
  1. CTC circulating tumor cell, DTC disseminated tumor cell, ER estrogen receptor, PR progesterone receptor, slCTC stem cell–like circulating tumor cell